Goldman Sachs Group Reiterates “€111.00” Price Target for Bayer (FRA:BAYN)

Bayer (FRA:BAYN) received a €111.00 ($129.07) price objective from Goldman Sachs Group in a report issued on Tuesday, September 25th. The brokerage currently has a “buy” rating on the healthcare company’s stock. Goldman Sachs Group’s target price indicates a potential upside of 45.86% from the company’s current price.

Other equities analysts have also issued reports about the stock. equinet set a €118.00 ($137.21) price target on shares of Bayer and gave the company a “buy” rating in a research report on Monday, June 4th. Sanford C. Bernstein set a €120.00 ($139.53) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, June 4th. Jefferies Financial Group set a €123.00 ($143.02) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, June 4th. UBS Group set a €130.00 ($151.16) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Friday, June 1st. Finally, Citigroup set a €132.00 ($153.49) target price on shares of Bayer and gave the stock a “buy” rating in a research report on Monday, June 18th. Seven research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of €98.80 ($114.88).

FRA BAYN traded down €1.22 ($1.42) on Tuesday, reaching €76.10 ($88.49). The company’s stock had a trading volume of 3,924,996 shares. Bayer has a 52 week low of €91.58 ($106.49) and a 52 week high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

See Also: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply